Home >> Partnering



Infectious Disease


Vaccine Development

Diagnostics and Imaging

Tumor Targets:

  1. Discovery -

  2. Via tumor immunization of mammalian hosts

  3. Rabbits, llamas, Goats, Mice

  4. Sampling the IgG immune repertoire of humans who are either titer positive or who have received cancer vaccines or immune synapse inhibitors (such as CTLA-4 or PD-1)

  5. Take advantage of in vivo patient response

  6. Screens

  7. Tumor specificity

  8. Death/differentiation

  9. Internalization target discovery for toxin conjugates

  10. Known, validated targets -

  11. For the less adventurous and risk-averse

  12. The number of validated targets are growing steadily

  13. Plenty of room for generic versions as early antibodies come off patent

Since the founding of North Coast in the fall of 2008, the company has been solely funded via partnerships with biotech/pharma companies.

North Coast is actively offering the use of BLAST to potential partners or companies interested in developing best-in-class antibodies that serve unmet medical needs or replace mediocre, approved antibodies to known validated targets.  By providing BLAST in multiple configurations, rapid high throughput analyses, and using multiple species; North Coast offers partners the ability to select those rare antibodies with favorable functional properties that other technologies fail to produce. 

Partnerships can be structured based on disease area(s), collaboration roles, degree of financial risk-sharing, and commercial territory. 


Personalized Medicine

Currently being investigated for institutional use at the local state level for generating tissue specific antibodies to patient tumors where the primary tissue of origin is no longer present and for patients for which there is no other option of treatment. 

Currently targeting both metastatic and primary malignancies of and not limited to:

  1. Prostate

  2. Ovarian

  3. Thyroid

  4. Bladder

  5. Breast in certain cases

  6. Thymic Carcinoid

  7. Endometriod/Cervical

  8. Multiple Myeloma

  9. Fibrolamellar Hepatocellular Carcinoma

While we are all attempting to find the single antibody that can help the greatest numbers of patients within a given tumor group, we feel that while this effort continues (with very little success) we should also use the tools that we have to give those who are sent home with 6 months to live a fighting chance.  We feel that we are morally obligated to pursue this given that the ability is here in technologies like BLAST which uses a class of therapeutic that is heavily validated in cancer treatment.

Viral and Bacterial Targets:

  1. Discovery -

  2. Via pathogen immunization of mammalian hosts

  3. Rabbits, llamas, Goats, Mice

  4. Sampling the IgG immune repertoire of humans

  5. Take advantage of in vivo patient response

  6. Screens

  7. Novel neutralization targets

  8. Direct binding to pathogen of interest for subsequent neutralization studies

  9. Secreted or cell surface-associated targets for detection or therapeutic depletion

  10. Known, validated targets -

  11. While not numerous, there are targets for various pathogens with which therapeutic antibodies have been raised (RSV, CMV, Flu)

Antibody induction of differentiation

By injecting rabbits or llamas with human tumor cell lines or stem cells, BLAST can be used to interrogate the millions of IgG’s generated against cell surface targets for induction of differentiation. 

While this is an obvious use of BLAST, the idea of antibodies inducing differentiation was validated serendipitously at Scripps (link).

NCB would like to pursue programs like this with interested partners looking for either novel targets that induce this effect or target receptors known to promote differentiation.

Host immune response monitoring

  1. Discovery -

  2. Analyze the breadth of the humoral autoimmune response in patients

  3. Reveal targets that are associated with pathology

  4. Define points of intervention for given autoimmune disorders

  5. Utilize the host immune response for generating fully human antibodies to known targets for use in other disease settings (a la anti-GMCSF, etc)

  6. Known targets

  7. Immunize mammalian species for generation of therapeutic antibodies to known auto-immune targets

Host immune response monitoring

  1. Humans -

  2. Monitor the epitope targeting of the vaccine of interest as it relates to efficacy in patients

  3. Can be done rapidly in conjunction with trials

  4. Utilize the host vaccine response to interrogate antibody response for associated therapeutic

  5. Antibody therapeutic for non-responders to vaccine

  6. Antibody co-injection for greater humoral output to efficacious vaccine epitope

  7. Other mammals -

  8. Immunize mammalian species for generation of vaccine-targeting antibodies that show efficacy

  9. For use as vaccine adjuvant or as a humanized therapeutic for those who cannot respond to vaccine

  10. Validate vaccine for induction of neutralizing antibodies followed by subsequent BLAST antibody rescue and target/epitope identification

Analyte detection

  1. Discovery -

  2. Discover targets that are shed or secreted in sera of various cancer groups

  3. Discover targets in sera associated with various pathogen infections

  4. Known targets -

  5. Generate high affinity capture reagents for known diagnostic targets

  6. Use rabbits or camelids to generate ultra high affinity and stable antibodies for use in traditional settings or in the field testing

Disease-associated target imaging

  1. For tumor targeting and imaging

  2. Generate ultra high affinity antibodies in rabbits or camelids for sensitive detection tools and for therapeutic antibody target patient validation

  3. For pathogen targeting and imaging